- Home
- DSGN vs AEF Comparison
DSGN vs AEF Comparison
Compare DSGN & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- AEF
- Stock Information
- Founded
- DSGN 2017
- AEF 1989
- Country
- DSGN United States
- AEF United States
- Employees
- DSGN N/A
- AEF N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- AEF Finance/Investors Services
- Sector
- DSGN Health Care
- AEF Finance
- Exchange
- DSGN Nasdaq
- AEF Nasdaq
- Market Cap
- DSGN 224.8M
- AEF 196.1M
- IPO Year
- DSGN 2021
- AEF N/A
- Fundamental
- Price
- DSGN $3.71
- AEF $5.65
- Analyst Decision
- DSGN Hold
- AEF
- Analyst Count
- DSGN 1
- AEF 0
- Target Price
- DSGN $4.00
- AEF N/A
- AVG Volume (30 Days)
- DSGN 93.8K
- AEF 92.5K
- Earning Date
- DSGN 08-04-2025
- AEF 01-01-0001
- Dividend Yield
- DSGN N/A
- AEF 7.13%
- EPS Growth
- DSGN N/A
- AEF N/A
- EPS
- DSGN N/A
- AEF 0.57
- Revenue
- DSGN N/A
- AEF N/A
- Revenue This Year
- DSGN N/A
- AEF N/A
- Revenue Next Year
- DSGN N/A
- AEF N/A
- P/E Ratio
- DSGN N/A
- AEF $8.86
- Revenue Growth
- DSGN N/A
- AEF N/A
- 52 Week Low
- DSGN $2.60
- AEF $4.40
- 52 Week High
- DSGN $7.77
- AEF $5.53
- Technical
- Relative Strength Index (RSI)
- DSGN 47.78
- AEF 62.03
- Support Level
- DSGN $3.66
- AEF $5.64
- Resistance Level
- DSGN $3.84
- AEF $5.77
- Average True Range (ATR)
- DSGN 0.25
- AEF 0.07
- MACD
- DSGN -0.02
- AEF -0.00
- Stochastic Oscillator
- DSGN 18.06
- AEF 73.21
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.